These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27358336)

  • 1. US health insurance is an obstacle to disease-modifying treatments in MS.
    Bourdette D; Patti F
    Neurology; 2016 Jul; 87(4):346-7. PubMed ID: 27358336
    [No Abstract]   [Full Text] [Related]  

  • 2. Working-age persons with multiple sclerosis and access to disease-modifying medications.
    Iezzoni LI; Ngo LH; Kinkel RP
    Mult Scler; 2008 Jan; 14(1):112-22. PubMed ID: 17893109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
    Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
    Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs and consequences of multiple sclerosis relapses: a managed care perspective.
    Morrow TJ
    J Neurol Sci; 2007 May; 256 Suppl 1():S39-44. PubMed ID: 17362995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sanz-Granda A; Garcia-Jurado L; Polanco-Sanchez C
    Rev Neurol; 2012 Apr; 54(7):446-7; author reply 447-8. PubMed ID: 22451133
    [No Abstract]   [Full Text] [Related]  

  • 10. [MS patients should get beta-interferon therapy early and for a long time].
    Ruutiainen J
    Duodecim; 2001; 117(17):1693-5. PubMed ID: 12181931
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
    Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.
    Azoulay D; Vachapova V; Shihman B; Miler A; Karni A
    J Neuroimmunol; 2005 Oct; 167(1-2):215-8. PubMed ID: 16083971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C; Izquierdo G; García-Ruiz A; Granell M; Brosa M
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating real-world clinical practice in multiple sclerosis economic evaluations.
    McQueen RB; Nair KV; Vollmer TL; Campbell JD
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):869-72. PubMed ID: 26295727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.